Viveve Medical Inc (NASDAQ:VIVE) Shorts Rose By 5.89% As Of Jun 27, 2018

June 27, 2018 - By Joe Cepeda

Viveve Medical Inc (NASDAQ:VIVE) recorded an increase of 5.89% in shares shorted. FINRA announced in June VIVE’s total 3.33M shares shorted. The up change of 5.89% from 3.14 million shares was reported. Viveve Medical Inc (NASDAQ:VIVE) has 281,800 shares average volume. It’ll cost 12 days for VIVE to recover its former position. Viveve Medical Inc float short is 37.34%.

Ticker’s shares touched $2.75 during the last trading session after 0.72% change.Currently Viveve Medical, Inc. is downtrending after 65.48% change in last June 27, 2017. VIVE has also 152,786 shares volume. VIVE underperformed by 78.05% the S&P 500.

Viveve Medical, Inc. designs, develops, makes, and markets medical devices for the non-invasive treatment of vaginal laxity.The firm is worth $85.99 million. The firm offers Geneveve, a non-invasive solution that includes the Viveve System, a radio frequency generator; a reusable hand piece and single-use treatment tip; and other consumable accessories.Currently it has negative earnings. It markets its products through sales employees and distributors in Asia, Europe, the Middle East, Latin America, the United States, Canada, and internationally.

For more Viveve Medical, Inc. (NASDAQ:VIVE) news brought out briefly go to:,,, or The titles are as follows: “Viveve Announces Settlement of Patent Infringement Litigation with Thermi” brought out on June 04, 2018, “After-Hours Stock Movers 06/18: (GEVO) (VIVE) (CL) Higher; (PAGS) (TELL) (DEA) Lower (more…)” on June 18, 2018, “5 Stocks Moving In Monday’s After-Hours Session” with a publish date: June 19, 2018, “Viveve Medical’s CMRF technology shows positive effect in women with SUI; shares up 12% after hours” and the last “Viveve to Present at Jefferies Global Healthcare Conference” with publication date: May 29, 2018.

Viveve Medical, Inc. (NASDAQ:VIVE) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.